Immunogenicity and safety of the multicomponent meningococcal B vaccine (4CMenB) in children and adolescents: a systematic review and meta-analysis.

[1]  M. Pizza,et al.  Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment. , 2017, The Lancet. Infectious diseases.

[2]  C. Signorelli,et al.  Italy's response to vaccine hesitancy: An innovative and cost effective National Immunization Plan based on scientific evidence. , 2017, Vaccine.

[3]  E. Moreira,et al.  Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial. , 2017, Vaccine.

[4]  B. Lefebvre,et al.  Impact of an Immunization Campaign to Control an Increased Incidence of Serogroup B Meningococcal Disease in One Region of Quebec, Canada , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[5]  E. Moreira,et al.  Immunogenicity and safety of concomitant administration of meningococcal serogroup B (4CMenB) and serogroup C (MenC-CRM) vaccines in infants: A phase 3b, randomized controlled trial. , 2017, Vaccine.

[6]  D. Toneatto,et al.  A phase III observer-blind randomized, controlled study to evaluate the immune response and the correlation with nasopharyngeal carriage after immunization of university students with a quadrivalent meningococcal ACWY glycoconjugate or serogroup B meningococcal vaccine. , 2017, Vaccine.

[7]  A. Pollard,et al.  Persistence of bactericidal antibodies following booster vaccination with 4CMenB at 12, 18 or 24months and immunogenicity of a fifth dose administered at 4years of age-a phase 3 extension to a randomised controlled trial. , 2017, Vaccine.

[8]  J. Macneil,et al.  Meningococcal Carriage Evaluation in Response to a Serogroup B Meningococcal Disease Outbreak and Mass Vaccination Campaign at a College—Rhode Island, 2015–2016 , 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  N. Andrews,et al.  Effectiveness and impact of a reduced infant schedule of 4CMenB vaccine against group B meningococcal disease in England: a national observational cohort study , 2016, The Lancet.

[10]  A. Pollard,et al.  Serum Bactericidal Antibody Responses of Adults Immunized with the MenB-4C Vaccine against Genetically Diverse Serogroup B Meningococci , 2016, Clinical and Vaccine Immunology.

[11]  H. Davies,et al.  Recommendations for Serogroup B Meningococcal Vaccine for Persons 10 Years and Older , 2016, Pediatrics.

[12]  B. Grenfell,et al.  Immunogenicity of a Meningococcal B Vaccine during a University Outbreak. , 2016, The New England journal of medicine.

[13]  D. Medini,et al.  Pooled-sera hSBA titres predict individual seroprotection in infants and toddlers vaccinated with 4CMenB. , 2016, Vaccine.

[14]  A. Pollard,et al.  Persistence of Bactericidal Antibodies After Infant Serogroup B Meningococcal Immunization and Booster Dose Response at 12, 18 or 24 Months of Age , 2016, The Pediatric infectious disease journal.

[15]  Y. Choe,et al.  Immunogenicity and safety of a multicomponent meningococcal serogroup B vaccine in healthy adolescents in Korea--A randomised trial. , 2016, Vaccine.

[16]  Philip S. Watson,et al.  Clinical experience with the meningococcal B vaccine, Bexsero(®): Prospects for reducing the burden of meningococcal serogroup B disease. , 2016, Vaccine.

[17]  M. Pizza,et al.  Effectiveness of Meningococcal B Vaccine against Endemic Hypervirulent Neisseria meningitidis W Strain, England , 2016, Emerging infectious diseases.

[18]  J. Findlow.  Vaccines for the prevention of meningococcal capsular group B disease: What have we recently learned? , 2016, Human vaccines & immunotherapeutics.

[19]  J. McVernon,et al.  Immune responses to a recombinant, four-component, meningococcal serogroup B vaccine (4CMenB) in adolescents: a phase III, randomized, multicentre, lot-to-lot consistency study. , 2015, Vaccine.

[20]  T. Vesikari,et al.  Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. , 2015, Vaccine.

[21]  R. Rappuoli,et al.  Prevention and control of meningococcal outbreaks: The emerging role of serogroup B meningococcal vaccines. , 2015, Vaccine.

[22]  D. Medini,et al.  MATS: Global coverage estimates for 4CMenB, a novel multicomponent meningococcal B vaccine. , 2015, Vaccine.

[23]  R. Cunney,et al.  A prolonged outbreak of invasive meningococcal disease in an extended Irish Traveller family across three Health Service Executive (HSE) areas in Ireland, 2010 to 2013. , 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

[24]  S. Block,et al.  A comparative evaluation of two investigational meningococcal ABCWY vaccine formulations: Results of a phase 2 randomized, controlled trial. , 2015, Vaccine.

[25]  X. Sáez-Llorens,et al.  Immunogenicity and safety of investigational vaccine formulations against meningococcal serogroups A, B, C, W, and Y in healthy adolescents , 2015, Human vaccines & immunotherapeutics.

[26]  Ly-Mee Yu,et al.  Persistence of specific bactericidal antibodies at 5 years of age after vaccination against serogroup B meningococcus in infancy and at 40 months , 2015, Canadian Medical Association Journal.

[27]  S. Faust,et al.  Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial , 2014, The Lancet.

[28]  G. Zuccotti,et al.  A phase II randomized controlled trial of a multicomponent meningococcal serogroup B vaccine, 4CMenB, in infants (II) , 2014, Human vaccines & immunotherapeutics.

[29]  C. Stein-Zamir,et al.  The Clinical Features and Long-term Sequelae of Invasive Meningococcal Disease in Children , 2014, The Pediatric infectious disease journal.

[30]  A. Pollard,et al.  Persistence of Bactericidal Antibodies to 5 Years of Age After Immunization With Serogroup B Meningococcal Vaccines at 6, 8, 12 and 40 Months of Age , 2014, The Pediatric infectious disease journal.

[31]  A. Pollard,et al.  A vaccine against serogroup B Neisseria meningitidis: dealing with uncertainty. , 2014, The Lancet. Infectious diseases.

[32]  G. Zuccotti,et al.  A phase 2 randomized controlled trial of a multicomponent meningococcal serogroup B vaccine (I) , 2014, Human vaccines & immunotherapeutics.

[33]  Ly-Mee Yu,et al.  Persistence of bactericidal antibodies following early infant vaccination with a serogroup B meningococcal vaccine and immunogenicity of a preschool booster dose , 2013, Canadian Medical Association Journal.

[34]  D. Medini,et al.  Bactericidal antibody against a representative epidemiological meningococcal serogroup B panel confirms that MATS underestimates 4CMenB vaccine strain coverage. , 2013, Vaccine.

[35]  J. Philip,et al.  Bactericidal Antibody Persistence 2 Years After Immunization With 2 Investigational Serogroup B Meningococcal Vaccines at 6, 8 and 12 Months and Immunogenicity of Preschool Booster Doses: A Follow-on Study to a Randomized Clinical Trial , 2013, The Pediatric infectious disease journal.

[36]  M. Valenzuela,et al.  Persistence of antibodies in adolescents 18−24 months after immunization with one, two, or three doses of 4CMenB meningococcal serogroup B vaccine , 2013, Human vaccines & immunotherapeutics.

[37]  T. Vesikari,et al.  Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials , 2013, The Lancet.

[38]  M. Pizza,et al.  Could the multicomponent meningococcal serogroup B vaccine (4CMenB) control Neisseria meningitidis capsular group X outbreaks in Africa? , 2013, Vaccine.

[39]  John P A Ioannidis,et al.  Neglected tropical diseases: survey and geometry of randomised evidence , 2012, BMJ : British Medical Journal.

[40]  M. Valenzuela,et al.  Immunogenicity and tolerability of a multicomponent meningococcal serogroup B (4CMenB) vaccine in healthy adolescents in Chile: a phase 2b/3 randomised, observer-blind, placebo-controlled study , 2012, The Lancet.

[41]  Ly-Mee Yu,et al.  Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules: a randomized controlled trial. , 2012, JAMA.

[42]  A. Gorringe,et al.  Bexsero: a multicomponent vaccine for prevention of meningococcal disease. , 2012, Human vaccines & immunotherapeutics.

[43]  N. Rouphael,et al.  Neisseria meningitidis: biology, microbiology, and epidemiology. , 2012, Methods in molecular biology.

[44]  J. Sterne,et al.  The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials , 2011, BMJ : British Medical Journal.

[45]  Georgia Salanti,et al.  Meta-Analysis of the Immunogenicity and Tolerability of Pandemic Influenza A 2009 (H1N1) Vaccines , 2011, PloS one.

[46]  M. Pizza,et al.  Early clinical experience with a candidate meningococcal B recombinant vaccine (rMenB) in healthy adults , 2011, Human vaccines.

[47]  D. Toneatto,et al.  The first use of an investigational multicomponent meningococcal serogroup B vaccine (4CMenB) in humans , 2011, Human Vaccines.

[48]  D. Toneatto,et al.  Immunogenicity and Safety of a Multicomponent Meningococcal Serogroup B Vaccine and a Quadrivalent Meningococcal CRM197 Conjugate Vaccine against Serogroups A, C, W-135, and Y in Adults Who Are at Increased Risk for Occupational Exposure to Meningococcal Isolates , 2010, Clinical and Vaccine Immunology.

[49]  A. Pollard,et al.  Multicenter, open-label, randomized phase II controlled trial of an investigational recombinant Meningococcal serogroup B vaccine with and without outer membrane vesicles, administered in infancy. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[50]  Ly-Mee Yu,et al.  Immunogenicity of Two Investigational Serogroup B Meningococcal Vaccines in the First Year of Life: A Randomized Comparative Trial , 2010, The Pediatric infectious disease journal.

[51]  R. Rappuoli,et al.  Measuring antigen-specific bactericidal responses to a multicomponent vaccine against serogroup B meningococcus. , 2010, Vaccine.

[52]  J. Ioannidis,et al.  Immunogenicity and adverse events of avian influenza A H5N1 vaccine in healthy adults: multiple-treatments meta-analysis. , 2009, The Lancet. Infectious diseases.

[53]  J. Donnelly,et al.  Bactericidal antibody is the immunologic surrogate of protection against meningococcal disease. , 2009, Vaccine.

[54]  M. Leinonen,et al.  ANTIGENIC SIMILARITIES BETWEEN BRAIN COMPONENTS AND BACTERIA CAUSING MENINGITIS Implications for Vaccine Development and Pathogenesis , 1983, The Lancet.